Association of the CYP1A1 rs4646903 polymorphism with susceptibility and severity of coronary artery disease

Document Type : Original article

Authors

1 Zanjan Metabolic Diseases Research Center, Zanjan University of Medical Sciences, Zanjan, Iran

2 Department of Cardiology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

3 Social Determinants of Health Research Center, Zanjan University of Medical Sciences, Zanjan, Iran

4 Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Zanjan University of Medical Sciences, Zanjan, Iran

Abstract

Given the significant physical, mental, and economic problems of coronary artery disease (CAD), it is important for communities to help reduce these costs. The Cytochrome P450 Family 1 Subfamily A Member 1) CYP1A1 (enzyme is known to cause coronary artery disease through various mechanisms. Therefore, it is important to investigate the polymorphisms that affect the activity of this enzyme. After collecting samples from 191 patients with angiographically verified CAD and 191 healthy individuals, genotyping for CYP1A1 rs4646903 polymorphism was carried out. Lipid profile was assessed by conventional colorimetric method. The results showed that the frequency of heterozygous and homozygous mutant genotypes of rs4646903 polymorphism was 36.6% and 5.2% in patients and 20.9% and 2.1% in controls, respectively. The heterozygous genotype (OR=2.24; 95% CI=1.30-3.84, P=0.003), homozygous mutant genotype (OR=3.97; 95% CI=1.05-14.98, P=0.042) and mutant C allele (OR=2.15; 95% CI=1.46-3.15, p <0.001) was significantly associated with CAD risk. Further analysis identified CYP1A1 rs4646903 polymorphism as a significant risk factor for early onset (P= 0.005) but not late onset (P=0.066) CAD. However, the frequency of heterozygous and homozygous mutant genotype of rs4646903 polymorphism did not differ significantly among the CAD patients with various number of stenotic vessel (P>0.05). In conclusion, the rs4646903 polymorphism contributed to the susceptibleness of people to CAD. 

Keywords

References

1. The National Heart L, and Blood Institute. Coronary Heart Disease Bethesda, washington: The National Heart, Lung, and Blood Institute; 2020 [updated 13 Nov  2020 Available from: https://www.nhlbi.nih.gov/health-topics/coronary-heart-disease.
2. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1736-1788.
3. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, Pletcher MA, Smith AE, Tang K, Yuan CW, Brown JC, Friedman J, He J, Heuton KR, Holmberg M, Patel DJ, Reidy P, Carter A, Cercy K, Chapin A, Douwes-Schultz D, Frank T, Goettsch F, Liu PY, Nandakumar V, Reitsma MB, Reuter V, Sadat N, Sorensen RJD, Srinivasan V, Updike RL, York H, Lopez AD, Lozano R, Lim SS, Mokdad AH, Vollset SE, Murray CJL. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet 2018;392:2052-2090.
4. Omura T. Heme-thiolate proteins. Biochem Biophys Res Commun 2005;338:404-409.
5. Parada H Jr, Steck SE, Cleveland RJ, Teitelbaum SL, Neugut AI, Santella RM, Gammon MD. Genetic polymorphisms of phase I metabolizing enzyme genes, their interaction with lifetime grilled and smoked meat intake, and breast cancer incidence. Ann Epidemiol 2017;27:208-214.e1.
6. Nida S, Javid B, Akbar M, Idrees S, Adil W, Ahmad GB. Gene variants of CYP1A1 and CYP2D6 and the risk of childhood acute lymphoblastic leukaemia; outcome of a case control study from Kashmir, India. Mol Biol Res Commun 2017;6:77-84.
7. Peng DD, Xie W, Yu ZX. Impact of interaction between CYP1A1 genetic polymorphisms and smoking on coronary artery disease in the Han of China. Clin Exp Hypertens 2017;39:339-343.
8. Henkler F, Stolpmann K, Luch A. Exposure to polycyclic aromatic hydrocarbons: bulky DNA adducts and cellular responses. Exp Suppl 2012;101:107-131.
9. Iwano S, Asanuma F, Nukaya M, Saito T, Kamataki T. CYP1A1-mediated mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbons. Biochem Biophys Res Commun 2005;337:708-712.
10. Kopf PG, Walker MK. 2,3,7,8-tetrachlorodibenzo-p-dioxin increases reactive oxygen species production in human endothelial cells via induction of cytochrome P4501A1. Toxicol Appl Pharmacol 2010;245:91-99.
11. Mohsenzadeh MS, Zanjani BR, Karimi G. Mechanisms of 2,3,7,8-tetrachlorodibenzo-p-dioxin- induced cardiovascular toxicity: An overview. Chem Biol Interact 2018;282:1-6.
12. Niki E. Do free radicals play causal role in atherosclerosis? Low density lipoprotein oxidation and vitamin E revisited. J Clin Biochem Nutr 2011;48:3-7.
13. Maliszewska-Kordybach B. Sources, concentrations, fate and effects of polycyclic aromatic hydrocarbons (PAHs) in the environment. Part A: PAHs in Air. Pol J Environ Stud 1999;8: 131-136.
14. Samanta SK, Singh OV, Jain RK. Polycyclic aromatic hydrocarbons: environmental pollution and bioremediation. Trends Biotechnol 2002;20:243-248.
15. Wang JB, Hung CH, Hung CH, Chang-Chien GP. Polychlorinated dibenzo-p-dioxin and dibenzofuran emissions from an industrial park clustered with metallurgical industries. J Hazard Mater 2009;161:800-807.
16. Menzie CA, Potocki BB, Santodonato J. Exposure to carcinogenic PAHs in the environment. Environ Sci Technol 1992;26:1278-1284.
17. Lv X, Sun J, Bi Y, Xu M, Lu J, Zhao L, Xu Y. Risk of all-cause mortality and cardiovascular disease associated with secondhand smoke exposure: a systematic review and meta-analysis. Int J Cardiol 2015;199:106-115.
18. Llobet JM, Domingo JL, Bocio A, Casas C, Teixido A, Muller L. Human exposure to dioxins through the diet in Catalonia, Spain: carcinogenic and non-carcinogenic risk. Chemosphere 2003;50:1193-1200.
19. Sachan S, Nair RR, Khanna A, Singh K. CYP1A1 and GSTM1 genes polymorphism and its association with endometriosis: A pilot study. Asian Pac J Reprod 2013;2:297-300.
20. Manfredi S, Federici C, Picano E, Botto N, Rizza A, Andreassi MG. GSTM1, GSTT1 and CYP1A1 detoxification gene polymorphisms and susceptibility to smoking-related coronary artery disease: a case-only study. Mutat Res 2007;621:106-112.
21. Pasalic D, Marinkovic N. Genetic polymorphisms of the CYP1A1, GSTM1, and GSTT1 enzymes and their influence on cardiovascular risk and lipid profile in people who live near a natural gas plant. Arh Hig Rada Toksikol 2017;68:46-52.
22. Zhang X, Lv S, Guo C, Shi C, Chi Y, Zhao L, Wang G, Wang Z. Gene-gene interaction between PPARG and CYP1A1 gene on coronary artery disease in the Chinese Han Population. Oncotarget 2017;8:34398-34404.
23. Cornelis MC, El-Sohemy A, Campos H. Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction. J Med Genet 2004;41:758-762.
24. Ghaznavi H, Soltanpour MS. Association study between rs2275913 genetic polymorphism and serum levels of IL-17A with risk of coronary artery disease. Mol Biol Res Commun 2020;9:35-40.
25. Motovali-Bashi M, Biglari M, Hojati Z, Hemati S, Khodadad K. Role of CYP1A1 MspI polymorphism in CYP1A1 gene with susceptibility to lung cancer in Iranian patients. J Res Med Sci 2012;8:10.
26. Calkin AC, Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol 2012;13:213-224.
27. Brinkmann J, Stolpmann K, Trappe S, Otter T, Genkinger D, Bock U, Liebsch M, Henkler F, Hutzler C, Luch A. Metabolically competent human skin models: activation and genotoxicity of benzo[a]pyrene. Toxicol Sci 2013;131:351-359.
28. Marinkovic N, Pasalic D, Potocki S. Polymorphisms of genes involved in polycyclic aromatic hydrocarbons' biotransformation and atherosclerosis. Biochem Med (Zagreb) 2013;23:255-265.
29. Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL. Oxidative Stress in Atherosclerosis. Curr Atheroscler Rep 2017;19:42.
30. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007;87:315-424.
31. Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N, Stefanadis C. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol 2012;10:4-18.
32. Kiani AA, Nazarabad VH, Ahmadi K, Anbari K, Ahmadi BB. Polymorphisms of endothelial nitric oxide synthase and hypoxia-inducible factor 1 alpha genes play a role in susceptibility to coronary artery disease. Biomed Res Therapy 2018;5:2688-2696.
33. Zhou B, Wang X, Li F, Wang Y, Yang L, Zhen X, Tan W. Mitochondrial activity and oxidative stress functions are influenced by the activation of AhR-induced CYP1A1 overexpression in cardiomyocytes. Mol Med Rep 2017;16:174-180.
34. Achour A, Zaag I, Gueddah L, Trimeche B, Slama FB, Zemni R. Role of CYP1A1 (T6235C) polymorphism and cigarette smoking in the development of coronary heart disease in Tunisian population. J Genet 2011;90:303-307.
35. Farzaneh F, Noghabaei G, Barouti E, Pouresmaili F, Jamshidi J, Fazeli A, Emamalizadeh B, Darvish H. Analysis of CYP17, CYP19 and CYP1A1 gene polymorphisms in Iranian women with breast cancer. Asian Pac J Cancer Prev 2016;17:23-26.
36. Jarvis MD, Palmer BR, Pilbrow AP, Ellis KL, Frampton CM, Skelton L, Doughty RN, Whalley GA, Ellis CJ, Yandle TG, Richards AM, Cameron VA. CYP1A1 MSPI (T6235C) gene polymorphism is associated with mortality in acute coronary syndrome patients. Clin Exp Pharmacol Physiol 2010;37:193-198.
37. Hersberger M. Genetic associations with coronary heart disease: meta-analyses of 12 candidate genetic variants. Gene 2015;558:299.
38. Tu G, Fang Z, Zhao Y, Wu Q. Association of +138I/D and Lys198Asn polymorphisms in the endothelin-1 gene with early onset of coronary artery disease among the Chinese Han population. Med Sci Monit 2020;26:e921542.

Files

Share

How to cite

Statistics